5-Amino-1MQ
← Back to LibraryCompound Profile
5-Amino-1MQ is reviewed here for cellular energy, stamina, and recovery.
Research Summary
Published literature searches and source-listed protocols
Cellular energy, Stamina, Recovery
Target context: NNMT
Limited or not established.
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
1mg
Dosing window
With Meals
Receptor / target
NNMT
Properties
Not listed
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 1mg 1x/day | Initiation dose. |
| Weeks 2 | 2mg 1x/day | First escalation. |
| Weeks 3-4 | 3mg 1x/day | Continued escalation. |
| Weeks 5-6 | 4mg 1x/day | Advanced phase. |
| Weeks 7-8 | 5mg 1x/day | Maximum protocol dose. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1: 4-Week Minimum Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1mg 1x/day | Baseline entry protocol. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 2: 8-Week Minimum Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1mg 1x/day | Standard initiation. |
| Weeks 5-8 | 2mg 1x/day | Step up for continued metabolic drive. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in metabolism, mitochondrial function, substrate use, exercise physiology, glucose handling, or endurance models. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: NNMT. Route(s): Subcutaneous. Dosing window on page: With Meals. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- NNMT inhibition is mainly supported by medicinal-chemistry and obesity-metabolism models; published work links NNMT blockade with changes in adipose metabolism and NAD-related pathways.
- Human dosing, long-term safety, and cancer-risk boundaries are not established by an approved label or large clinical program.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Week 1, 1mg 1x/day; Alternative Titration 1: 4-Week Minimum Protocol: Weeks 1-4, 1mg 1x/day.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor sleep, heart rate, blood pressure, glucose response, training load, appetite, and stimulant overlap.
Selected medical sources
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active malignancy: NNMT inhibition increases intracellular NAD+ and SIRT1 activity, which in normal cells promotes health and longevity; in cancer cells, elevated NAD+ can fuel tumor metabolic demands and enhance DNA repair capacity that helps cancer cells evade treatment.
- History of cancer: theoretical concern; assess risk-benefit individually.
- Concurrent use with MAO inhibitors (MAOIs): 5-Amino-1MQ contains a quinolinium structure; potential pharmacological interaction with monoamine oxidase inhibition pathways is not characterized but warrants caution.
- Known hypersensitivity to 5-Amino-1MQ or quinolinium-based compounds.
- Pregnancy: no safety data; NAD+ pathway manipulation during fetal development is not established as safe.
- Breastfeeding: no safety data.
- Individuals with severely compromised renal or hepatic function: elimination and metabolism not characterized in organ impairment.
- Pediatric use: no data.
- Concurrent use with agents that also raise NAD+ (injectable NAD+, NMN, NR supplementation): the combined NAD+ elevation may be excessive in cancer-susceptible individuals; monitor accordingly in others.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Insomnia or sleep disruption: the most commonly reported side effect; increased cellular energy production and metabolic rate elevation interfere with sleep onset; mitigated by strict morning or with-meal dosing, never in the evening.
- Mild anxiety and jitteriness: sympathomimetic-like stimulation from metabolic rate increase; not from direct adrenergic receptor agonism but from downstream mitochondrial activation; dose-dependent.
- Injection site irritation: redness, soreness at the subcutaneous site; standard peptide injection response.
- Mild headache: reported in early weeks; likely related to cellular metabolic shifts and NAD+ pathway activation.
- Gastrointestinal discomfort: mild nausea or GI upset; more common if taken without food (hence the "With Meals" dosing requirement).
- Transient fatigue in the post-dose window: paradoxical; as cells shift metabolic programs, a short window of fatigue may precede the sustained energy improvement.
- Potential overstimulation of NAD+ production: theoretical; excessive SIRT1 activation could alter epigenetic regulation in ways not fully characterized in long-term human research.
- No endocrine disruption: 5-Amino-1MQ has no known activity at hormone receptors; does not affect cortisol, testosterone, estrogen, or thyroid hormone pathways.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.